Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.76 |
| ▸ | LIFR | P42702 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179357 | 0.93 | NR1H4 (0.88) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL1180584 | 0.92 | NR1H4 (0.87) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL1179745 | 0.92 | NR1H4 (0.85) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL1179921 | 0.89 | NR1H4 (0.72) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL1180442 | 0.88 | NR1H4 (0.77) | NR1H4LIFRCYP1A2CYP2C9 | |
| SCHEMBL1180241 | 0.88 | NR1H4 (0.72) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL2114524 | 0.87 | NR1H4 (0.85) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL3642513 | 0.87 | NR1H4 (0.57) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL1179388 | 0.87 | NR1H4 (0.73) | NR1H4LIFRCYP1A2CYP2C9NR1I2 | |
| SCHEMBL21624442 | 0.86 | NR1H4 (1.00) | NR1H4LIFRCYP1A2CYP2C9NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| EP-2173174-A1 | FARNESOID X RECEPTOR AGONISTS | GlaxoSmithKline LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005998-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885LIFR 1950/4885CYP1A2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.